Biological Methods for Studying Radiosensitization
Many aspects of research in radiobiology and radiotherapy depend upon the belief that hypoxic cells exist in human tumours, and that these radioresistant cells determine whether or not the tumour will be cured or will recur after radiotherapy. Hypoxic cells are believed to develop because of the imbalance between tumour cell production and the growth of blood vessels to provide nutrients, including oxygen (1,2). A corded structure similar to that shown in Figure 1 was first demonstrated by Thomlinson and Gray in human lung tumours (3). They postulated that necrosis at 100–150 μm resulted from severe hypoxia and that a rim of hypoxic cells which were about to die existed at the boundary between the viable and dead tissue.
KeywordsBiological Method Nerve Conduction Velocity Hypoxic Cell Enhancement Ratio Tumour Concentration
Unable to display preview. Download preview PDF.
- 2.D. G. Hirst, and J. Denekamp, Tumour cell proliferation in relation to the vasculature, Cell and Tissue Kinet. 12:31 (1979).Google Scholar
- 4.R. H. Thomlinson, Oxygen Therapy: Biological Considerations, in “Modern Trends in Radiotherapy”, T. Deeley and C. P. Wood, eds., Butterworths (1967).Google Scholar
- 5.J. Denekamp, and J. F. Fowler, Cell proliferation kinetics and radiation therapy, in “Cancer: A Comprehensive Treatise”, Vol. 6, ch. 4, F. F. Becker, ed., Plenum, New York and London (1977).Google Scholar
- 11.J. Denekamp, Is any single in situ assay of tumour response adequate? Brit. J. Cancer 41:Suppl. IV, 56 (1980).Google Scholar
- 15.J. Denekamp, N.J. McNally, J. F. Fowler, and M. C. Joiner, Misonidazole in fractionated radiotherapy: little and often? Brit. J. Radiol. (in press).Google Scholar
- 19.G.E. Adams, E. D. Clarke, I. R. Flockhart, R. S. Jacobs, D. S. Sehmi, I. J. Stratford, P. Wardman, M. E. Watts, J. Parrick, R. G. Wallace, and C. E. Smithen, Structure-activity relationships in the development of hypoxic cell radiosensitizers. I. Sensitization efficiency, Int. J. Radiat. Biol. 35: 133 (1979).CrossRefGoogle Scholar
- 20.P. Wardman, The use of nitroaromatic compounds as hypoxic cell radiosensitizers, Curr. Top. Radiat. Res. Quart. 11:347 (1977).Google Scholar
- 22.D. G. Hirst, B. Vojnovic, I.J. Stratford, and E. L. Travis, The effect of the rädiosensitizer misonidazole on motor nerve conduction velocity in the mouse, Brit. J. Cancer 37 Suppl. III, 237 (1978).Google Scholar
- 24.C. Clarke, K. B. Dawson, P. W. Sheldon, D. J. Chaplin, I. J. Stratford, and G. E. Adams, A quantitative cytochemical method for assessing the neurotoxicity of misonidazole, in “Radiation Sensitizers: Their use in the Clinical Management of Cancer”, L. W. Brady, ed., Masson Publishing Inc., New York (1980).Google Scholar
- 27.C. E. Smithen, E. D. Clarke, J. A. Dale, R. S. Jacobs, P. Wardman, M. E. Watts, and M. Woodcock, Novel (nitro-1-imidazolyl) alkanolamines as potential radiosensitizers with improved therapeutic properties, Cancer Clin. Trials (in press).Google Scholar
- 29.G. E. Adams, J. F. Fowler, and P. Wardman, eds½. Hypoxic cell sensitizers in radiobiology and radiotherapy, Brit. J. Cancer 37, Suppl. III (1978).Google Scholar
- 31.C. M. Rose, J. L. Millar, J. H. Peacock, T. A. Phelps, and T. C. Stephens, Differential enhancement of melphalan cytotoxicity in tumor and normal tissue by misonidazole, Cancer Clin. Trials (in press).Google Scholar